Floatz logo

BICALUTAMIDE

Polycystic Ovary Syndrome

University of California, San FranciscoSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

60 Active assets in the Polycystic Ovary Syndrome cohort.

Asset / SponsorPhaseRating
Human Chorionic Gonadotropin
Eman Basuni Ebrahim Mowad
Phase 4BBB
Liraglutide
Peking University Third Hospital
Phase 4BBB
Semaglutide
Methodist Health System
Phase 4BBB
FOLLITROPIN BETA
Universitair Ziekenhuis Brussel
Phase 4BBB
Drospirenone
Ege University
Phase 4BBB

View all 49 →

Same molecule, other indications

BICALUTAMIDE is also rated in:

prostate adenocarcinomaActive
BB
Indicative · Phase 3
69 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
prostate cancerActive
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →